Bringing the Oncology Community Together

Minimal Dosing Strategy With Gemtuzumab Ozogamicin Improves Survival in Older Patients With Acute Myeloid Leukemia

David Hawk
Published Online: Sunday, December 11, 2011
ASH centralThe addition of fractionated doses of gemtuzumab ozogamicin (GO) to a standard chemotherapy regimen improved both event-free, and overall survival (OS) of newly diagnosed patients with acute myeloid leukemia (AML), aged 50 to 70 years, according to results from a Phase III trial reported at the 53rd Annual Meeting of the American Society of Hematology.
“With this research we are encouraged that gemtuzumab may be able to deliver better overall outcomes for these AML patients with limited alternatives,” said lead investigator, Sylvie Castaigne, MD, professor, Department of Hematology at Hôpital de Versailles,Versailles, France.
Gemtuzumab ozogamicin (GO), a humanized monoclonal antibody linked to a cytotoxic agent, is targeted to the CD33 cell surface antigen that is present on roughly 90% of blast cells in AML. When the drug was first developed it was seen as a promising agent in treating AML; however, studies performed after the drug’s approval in 2000 raised questions about excess toxicity. These concerns persisted, and in June of 2010, the manufacturer voluntarily withdrew GO from the US market.
“In its initial development, gemtuzumab was dosed 9 mg/m2,” said Castaigne, “but this dose was so toxic we were unable to combine it with standard chemotherapy.” This led Castaigne and her colleagues to develop a new fractionated regimen. “We give 3 mg/m2 on day 1, 4, and 7, which allows us to combine it with chemotherapy. Using it this way we were able to demonstrate more efficacy,” and with less toxicity than that observed with the 9-mg bolus dose. The approach was validated in 2 previous Phase II trials.  
In the current investigation, the research team at the Acute Leukemia French Association designed a Phase III, prospective, open-label, randomized trial, enrolling treatment naïve, de novo patients with AML, ages 50 to 70 years. Study participants were randomized to 1 of 2 treatment arms — either standard chemotherapy with daunorubicin/ara-C (DC: n=134) or DC plus GO (DCGO, n=137). Study endpoints were event-free survival (EFS), disease-free survival (DFS), OS, and safety over a 3-year follow-up period.
Response rates to treatment were as follows: overall, CR+CRp was achieved in 220/271 patients (77%): 100/134 (75%) in the DC arm (control) versus 110/137 (80%) in the DCGO arm (P=0.31). Significantly, primary resistant AML rate was 29/134 (22%) after DC versus 18/137 (13%) after DCGO (P=0.08). Regarding safety at induction, there were 5/134 (4%) induction deaths in the DC arm and 9/137 (6%) in the DCGO arm (P=0.41).

>>>Return to the main conference coverage page.
Related Articles
Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death
A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer
The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer
Related Videos
No Result Found
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
OncLive Resources

OncLive TV
Oncology Nurses
Web Exclusives

About Us
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.